Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | SPHK1 | Q9NYA1 | 7/20 | 0.35 |
| ▸ | SPHK2 | Q9NRA0 | 6/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4351228 | 1.00 | EPHX1 (0.57) | EPHX1ALDH1A1ALOX5CYP1A2TDP1 | |
| SCHEMBL4351572 | 1.00 | EPHX1 (0.57) | EPHX1ALDH1A1ALOX5CYP1A2TDP1 | |
| SCHEMBL4369564 | 1.00 | EPHX1 (0.57) | EPHX1ALDH1A1ALOX5CYP1A2TDP1 | |
| SCHEMBL4364245 | 1.00 | EPHX1 (0.57) | EPHX1ALDH1A1ALOX5CYP1A2TDP1 | |
| SCHEMBL4354706 | 1.00 | EPHX1 (0.57) | EPHX1ALDH1A1ALOX5CYP1A2TDP1 | |
| SCHEMBL4357673 | 1.00 | EPHX1 (0.57) | EPHX1ALDH1A1ALOX5CYP1A2TDP1 | |
| SCHEMBL4360060 | 0.98 | EPHX1 (0.53) | EPHX1ALDH1A1ALOX5CYP1A2TDP1 | |
| SCHEMBL4365575 | 0.92 | EPHX1 (0.45) | EPHX1ALDH1A1ALOX5CYP1A2 | |
| SCHEMBL4354747 | 0.89 | EPHX1 (0.48) | EPHX1ALDH1A1ALOX5CYP1A2TDP1 | |
| SCHEMBL4354752 | 0.89 | EPHX1 (0.48) | EPHX1ALDH1A1ALOX5CYP1A2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090035702-A1 | PROCESS FOR PRODUCING COMPOUND HAVING ACID-LABILE GROUP | KYOWA HAKKO CHEMICAL CO., LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| US-20060177763-A1 | Method for producing compound having acid-labile group | KYOWA HAKKO CHEMICAL CO., LTD. (JP) | 2006-08-10 | — | — | US | disclosed |
| EP-1661918-A1 | METHOD FOR PRODUCING COMPOUND HAVING ACID-LABILE GROUP | Kyowa Hakko Chemical Co., Ltd. (JP) | 2006-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090035702-A1 | PROCESS FOR PRODUCING COMPOUND HAVING ACID-LABILE GROUP | AGL, HACL2, ARL1 | EPHX1 330/4885ALDH1A1 367/4885ALOX5 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.